P272 NMD670, a novel first-in-class muscle ClC-1 inhibitor, improves symptoms of myasthenia gravis: a randomized, single-dose, double-blind, placebo-controlled study
| Autor: | Quiroz, J., Ruijs, T., Grønnebæk, TS., de Cuba, K., Heuberger, J., de Kam, M., Koopmans, I., de Goede, A., Tannemaat, M., Vershuuren, J., Bold, J., Jensen, K., Flagstad, P., Petersen, T., Chin, E., Hutchison, J., Groeneveld, G., Pedersen, T. |
|---|---|
| Zdroj: | In Neuromuscular Disorders October 2023 33 Supplement 1:S178-S178 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect